ESPE2022 Poster Category 1 Pituitary, Neuroendocrinology and Puberty (77 abstracts)
Introduction: Today, excessive nutrition and obesity are the leading environmental factors affecting this puberty. We planned to investigate the prevalence of obesity in our patients who received GnRH analog therapy in our clinic, and the distribution, clinical features and laboratory findings of our patients with and without obesity.
Methods: In the study, female patients who received GnRH analog therapy in the Pediatric Endocrinology outpatient clinic of Ankara City Hospital between August 2019 and December 2021 were divided into 2 groups, obese and non-obese, according to body mass index (BMI). SPSS 26.0 program was used for statistical analysis. The rates of the two independent groups were compared with the “Chi-Square” test, the medians of the two independent groups with the “Mann-Whitney U” test, and the mean of the two independent groups with the “Student t-test”. Statistically, P<0.05 was considered significant.
Results: The mean±SDS age of 108 patients who received GnRH analogue therapy was 8.2±0.9 years. The most common complaints of the cases were breast enlargement 69.4% (n:76), hair growth 6.5% (n:7), breast growth and hair growth together 17.6% (n:19), menarche 5.6% (n:6). The most common breast tanner stage at presentation was stage 3; pubic hair was stage 1. While 26.9% (n: 29) of the cases were obese, 73.1% (n: 79) were non-obese. The mean±SDS age at presentation was 8.3±0.8 in obese cases and 8.2±0.9 in non-obese cases. In the physical examination at presentation, the most common breast tanner staging was stage 3 in both obese and non-obese cases. Obese cases were taller at presentation than the non-obese group (P=0.004). In addition, the bone age of the obese group at the time of admission was found to be higher than the non-obese group (P=0.01).
Conclusion: In our study, the age of admission and initiation of treatment in obese cases and non-obese cases were similar. Bone age at the time of admission of obese cases was more advanced, and it is compatible with the literature, and also their height at admission was longer in obese cases It is considered as a positive gain in terms of height gain during the treatment.
15 Sep 2022 - 17 Sep 2022